Key facts
- Alithea Genomics’s last known valuation is $66.4M (Mar 2026).
- It has raised $9.1M; the latest was Seed Round ($8.9M) in Mar 2026.
- Notable investors include Venture Kick, Ecole Polytechnique Federale de Lausanne, Kickfund, Zürcher Kantonalbank, Biopole — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Alithea Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Alithea Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alithea Genomics
Developer of cost-efficient transcriptomics designed to perform biomedical discoveries. The company's transcriptomics uses its proprietary technology to optimize the operational costs of Ribonucleic acid sequencing and significantly increase the throughput of analyzed samples, enabling pharmaceutical companies to perform biomedical research.
- Sector
- Healthcare
- HQ
- Epalinges, Switzerland
- Founded
- 2020
- Employees
- 34
- Website
- alitheagenomics.com/
- Ownership
- Privately Held (backing)
Alithea Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alithea Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alithea Genomics in its N-PORT filings yet. We sweep new filings monthly.